Cargando…

Immunotherapy for Dogs: Running Behind Humans

A number of excellent reviews on the potential of canine cancer immunotherapy are available, but many extrapolate from observations in humans when in fact only very few immunotherapies have been developed for canines that have shown efficacy in well-designed studies. Pharmaceutical and biotech compa...

Descripción completa

Detalles Bibliográficos
Autor principal: Klingemann, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807660/
https://www.ncbi.nlm.nih.gov/pubmed/29459862
http://dx.doi.org/10.3389/fimmu.2018.00133
_version_ 1783299316682588160
author Klingemann, Hans
author_facet Klingemann, Hans
author_sort Klingemann, Hans
collection PubMed
description A number of excellent reviews on the potential of canine cancer immunotherapy are available, but many extrapolate from observations in humans when in fact only very few immunotherapies have been developed for canines that have shown efficacy in well-designed studies. Pharmaceutical and biotech companies are aware that the market for more expensive immunotherapies in canines is limited resulting in limited funding for clinical trials. However, dogs and other pets deserve access to this new form of cancer therapy. The purpose of this brief review is to summarize the current status of available immunotherapies for dogs and their near-term prospects, provided we can effectively translate discoveries and progress in humans to canines.
format Online
Article
Text
id pubmed-5807660
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58076602018-02-19 Immunotherapy for Dogs: Running Behind Humans Klingemann, Hans Front Immunol Immunology A number of excellent reviews on the potential of canine cancer immunotherapy are available, but many extrapolate from observations in humans when in fact only very few immunotherapies have been developed for canines that have shown efficacy in well-designed studies. Pharmaceutical and biotech companies are aware that the market for more expensive immunotherapies in canines is limited resulting in limited funding for clinical trials. However, dogs and other pets deserve access to this new form of cancer therapy. The purpose of this brief review is to summarize the current status of available immunotherapies for dogs and their near-term prospects, provided we can effectively translate discoveries and progress in humans to canines. Frontiers Media S.A. 2018-02-05 /pmc/articles/PMC5807660/ /pubmed/29459862 http://dx.doi.org/10.3389/fimmu.2018.00133 Text en Copyright © 2018 Klingemann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Klingemann, Hans
Immunotherapy for Dogs: Running Behind Humans
title Immunotherapy for Dogs: Running Behind Humans
title_full Immunotherapy for Dogs: Running Behind Humans
title_fullStr Immunotherapy for Dogs: Running Behind Humans
title_full_unstemmed Immunotherapy for Dogs: Running Behind Humans
title_short Immunotherapy for Dogs: Running Behind Humans
title_sort immunotherapy for dogs: running behind humans
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807660/
https://www.ncbi.nlm.nih.gov/pubmed/29459862
http://dx.doi.org/10.3389/fimmu.2018.00133
work_keys_str_mv AT klingemannhans immunotherapyfordogsrunningbehindhumans